Autoimmune anti-DNA and anti-phosphatidylserine antibodies predict development of severe COVID-19

Gomes, Cláudia; Zuniga, Marisol; Crotty, Kelly; Qian, Kun; Tovar, Nubia Catalina; Lin, Lawrence Hsu; Argyropoulos, Kimon V.; Clancy, Robert M.; Izmirly, Peter; Buyon, Jill P.; Lee, David C; Yasnot, María Fernanda; Li, Huilin; Cotzia, Paolo; Rodrı́guez, Ana

doi:10.26508/lsa.202101180

Cited by 20 publications

(16 citation statements)

References 40 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, the presence of anti-DNA and anti-PS autoantibodies may play an important role in the pathogenesis of COVID-19 and could be sought as a predictive biomarker for disease severity and specific clinical manifestations. Another study also correlated the presence of autoantibodies against the lung protective protein Annessin-A2 with the mortality of COVID-19 patients [ 352 , 353 ]. The innate immune response is non-specific, because it is not influenced by previous exposure to other pathogens.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast

Inchingolo

Malcangi

Ceci

et al. 2022

IJMS

View full text Add to dashboard Cite

Background: The recent COVID-19 pandemic produced a significant increase in cases and an emergency state was induced worldwide. The current knowledge about the COVID-19 disease concerning diagnoses, patient tracking, the treatment protocol, and vaccines provides a consistent contribution for the primary prevention of the viral infection and decreasing the severity of the SARS-CoV-2 disease. The aim of the present investigation was to produce a general overview about the current findings for the COVID-19 disease, SARS-CoV-2 interaction mechanisms with the host, therapies and vaccines’ immunization findings. Methods: A literature overview was produced in order to evaluate the state-of-art in SARS-CoV-2 diagnoses, prognoses, therapies, and prevention. Results: Concerning to the interaction mechanisms with the host, the virus binds to target with its Spike proteins on its surface and uses it as an anchor. The Spike protein targets the ACE2 cell receptor and enters into the cells by using a special enzyme (TMPRSS2). Once the virion is quietly accommodated, it releases its RNA. Proteins and RNA are used in the Golgi apparatus to produce more viruses that are released. Concerning the therapies, different protocols have been developed in observance of the disease severity and comorbidity with a consistent reduction in the mortality rate. Currently, different vaccines are currently in phase IV but a remarkable difference in efficiency has been detected concerning the more recent SARS-CoV-2 variants. Conclusions: Among the many questions in this pandemic state, the one that recurs most is knowing why some people become more seriously ill than others who instead contract the infection as if it was a trivial flu. More studies are necessary to investigate the efficiency of the treatment protocols and vaccines for the more recent detected SARS-CoV-2 variant.

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast

Inchingolo

Malcangi

Ceci

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Similar to malaria, high levels of circulating autoantibodies have been reported in COVID-19 patients, but surprisingly, circulating immune complexes were not increased in these patients. The autoantibodies include similar targets to malaria, such as PS and dsDNA ( 51 ), but also expand to newer targets such Annexin A2 ( 52 ), that have not been studied in malaria patients. The autoantibody repertoire seems to be broad during COVID-19 and is not clear if it’s selected preferably against any autoantigen although their pathogenic role has been highly suggested by multiple studies ( 53 , 54 ).…”

Section: Lessons From Malaria Applied To Covid-19 and Other Infectionsmentioning

confidence: 99%

Autoantibodies during infectious diseases: Lessons from malaria applied to COVID-19 and other infections

Rivera-Correa

Rodrı́guez

2022

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

Autoimmunity is a common phenomenon reported in many globally relevant infections, including malaria and COVID-19. These and other highly inflammatory diseases have been associated with the presence of autoantibodies. The role that these autoantibodies play during infection has been an emerging topic of interest. The vast numbers of studies reporting a range of autoantibodies targeting cellular antigens, such as dsDNA and lipids, but also immune molecules, such as cytokines, during malaria, COVID-19 and other infections, underscore the importance that autoimmunity can play during infection. During both malaria and COVID-19, the presence of autoantibodies has been correlated with associated pathologies such as malarial anemia and severe COVID-19. Additionally, high levels of Atypical/Autoimmune B cells (ABCs and atypical B cells) have been observed in both diseases. The growing literature of autoimmune B cells, age-associated B cells and atypical B cells in Systemic Lupus erythematosus (SLE) and other autoimmune disorders has identified recent mechanistic and cellular targets that could explain the development of autoantibodies during infection. These new findings establish a link between immune responses during infection and autoimmune disorders, highlighting shared mechanistic insights. In this review, we focus on the recent evidence of autoantibody generation during malaria and other infectious diseases and their potential pathological role, exploring possible mechanisms that may explain the development of autoimmunity during infections.

show abstract

“…Thus, from an immunological point of view, the immune reaction in response to SARS-CoV-2 infections shares similarities to autoimmune diseases. In this context it was reported that COVID-19 patients carrying antinuclear antibodies (ANAs), antiphospholipid antibodies or anti-SS-A/Ro show more severe COVID-19 courses than patients devoid of these autoantibodies [7][8][9][10]. Interestingly, in non-symptomatic COVID-19 patients and patients with only mild disease courses, an age-dependent tendency towards the development of autoantibodies such as anti-cyclic citrullinated peptides (CCP)-IgG and anti-tissue transglutaminase (TTG)-IgA antibodies was also detected [11].…”

Section: Introductionmentioning

confidence: 99%

Homologous and Heterologous Anti-COVID-19 Vaccination Does Not Induce New-Onset Formation of Autoantibodies Typically Accompanying Lupus Erythematodes, Rheumatoid Arthritis, Celiac Disease and Antiphospholipid Syndrome

et al. 2022

View full text Add to dashboard Cite

The COVID-19 pandemics has caused the death of almost six million people worldwide. In order to establish collective immunity, the first vaccines that were approved in Germany were the vector virus-based vaccine Vaxzevria and the mRNA vaccines Comirnaty and Spikevax, respectively. As it was reported that SARS-CoV-2 can trigger autoimmunity, it is of significant interest to investigate whether COVID-19 vaccines evoke the formation of autoantibodies and subsequent autoimmunity. Here, we analyzed immune responses after different vaccination regimens (mRNA/mRNA, Vector/Vector or Vector/mRNA) with respect to anti-SARS-CoV-2-specific immunity and the development of autoantibodies well known for their appearance in distinct autoimmune diseases. We found that anti-SARS-CoV-2 antibody levels were 90% lower after Vector/Vector vaccination compared to the other vaccinations and that Vector/mRNA vaccination was more effective than mRNA/mRNA vaccination in terms of IgM and IgA responses. However, until 4 months after booster vaccination we only detected increases in autoantibodies in participants with already pre-existing autoantibodies whereas vaccinees showing no autoantibody formation before vaccination did not respond with sustained autoantibody production. Taken together, our study suggests that all used COVID-19 vaccines do not significantly foster the appearance of autoantibodies commonly associated with lupus erythematodes, rheumatoid arthritis, Celiac disease and antiphospholipid-syndrome but provide immunity to SARS-CoV-2.

show abstract

Autoimmune anti-DNA and anti-phosphatidylserine antibodies predict development of severe COVID-19

Cited by 20 publications

References 40 publications

Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast

Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast

Autoantibodies during infectious diseases: Lessons from malaria applied to COVID-19 and other infections

Homologous and Heterologous Anti-COVID-19 Vaccination Does Not Induce New-Onset Formation of Autoantibodies Typically Accompanying Lupus Erythematodes, Rheumatoid Arthritis, Celiac Disease and Antiphospholipid Syndrome

Contact Info

Product

Resources

About